MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

3.96 -1.25

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.88

Max

4.08

Põhinäitajad

By Trading Economics

Sissetulek

5.8M

-5.6M

Müük

4.1M

46M

Kasumimarginaal

-12.243

Töötajad

688

EBITDA

4.4M

-11M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+23.15% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

17M

504M

Eelmine avamishind

5.21

Eelmine sulgemishind

3.96

Uudiste sentiment

By Acuity

50%

50%

159 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. okt 2025, 18:13 UTC

Suurimad hinnamuutused turgudel

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. okt 2025, 17:05 UTC

Suurimad hinnamuutused turgudel

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17. okt 2025, 15:03 UTC

Suurimad hinnamuutused turgudel

Obook Shares Sink Following Public Debut

17. okt 2025, 14:41 UTC

Suurimad hinnamuutused turgudel

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17. okt 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. okt 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. okt 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. okt 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. okt 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. okt 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. okt 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. okt 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. okt 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. okt 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. okt 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. okt 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. okt 2025, 15:56 UTC

Tulu

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. okt 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17. okt 2025, 14:58 UTC

Market Talk

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17. okt 2025, 14:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 14:35 UTC

Market Talk
Tulu

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

23.15% tõus

12 kuu keskmine prognoos

Keskmine 5 USD  23.15%

Kõrge 8 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

159 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat